trending Market Intelligence /marketintelligence/en/news-insights/trending/9wPoFJ96DgX-DrbQC3yiSA2 content esgSubNav
In This List

Report: Mallinckrodt seeks sale of generic drug unit

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Report: Mallinckrodt seeks sale of generic drug unit

Mallinckrodt PLC is looking at the possibility of a sale of its generic drug unit, Reuters reported May 30, citing "people familiar with the matter."

A deal for the unit might be valued at about $2 billion. There is no guarantee the talks will lead to a deal, according to the sources.

The company has reportedly appointed Credit Suisse Group AG to run a sale process for the business.